Carisma Therapeutics Appoints New CMO and Board Member
Ticker: CARM · Form: 8-K · Filed: Oct 30, 2024 · CIK: 1485003
Sentiment: neutral
Topics: executive-appointment, board-of-directors, personnel-change
TL;DR
Carisma adds pharma heavyweights Epstein & Kelly to leadership. Big moves ahead?
AI Summary
Carisma Therapeutics Inc. announced on October 24, 2024, the appointment of Dr. Steven D. F. R. Kelly as Chief Medical Officer and Dr. David M. Epstein as a new member of its Board of Directors. Dr. Kelly previously held a senior medical role at Bristol Myers Squibb, and Dr. Epstein is the former CEO of Novartis Oncology.
Why It Matters
The appointment of experienced executives like Dr. Kelly and Dr. Epstein suggests Carisma Therapeutics is strengthening its leadership team, potentially to advance its drug development pipeline.
Risk Assessment
Risk Level: medium — The filing details executive appointments and board changes, which are standard corporate actions but can signal strategic shifts or challenges within the company.
Key Players & Entities
- Carisma Therapeutics Inc. (company) — Registrant
- Dr. Steven D. F. R. Kelly (person) — Appointed Chief Medical Officer
- Dr. David M. Epstein (person) — Appointed to Board of Directors
- Bristol Myers Squibb (company) — Dr. Kelly's former employer
- Novartis Oncology (company) — Dr. Epstein's former role as CEO
FAQ
What are the specific responsibilities of Dr. Steven D. F. R. Kelly as the new Chief Medical Officer?
The filing states Dr. Kelly has been appointed Chief Medical Officer, implying leadership over the company's medical and clinical development strategies, though specific duties are not detailed in this 8-K.
What is Dr. David M. Epstein's prior experience that makes him a valuable addition to the Board of Directors?
Dr. Epstein is noted as the former CEO of Novartis Oncology, indicating significant leadership and strategic experience in the pharmaceutical industry.
When did these appointments become effective?
The earliest event reported in the filing is dated October 24, 2024, which is the effective date for these appointments.
Does this filing mention any changes to Carisma Therapeutics' overall strategy?
This specific 8-K filing focuses on personnel changes (appointments of a CMO and a board member) and does not explicitly detail broader strategic shifts.
Are there any financial implications mentioned in this filing regarding these appointments?
This filing pertains to the departure and election of officers and directors and compensatory arrangements, but specific financial figures related to these appointments are not provided in this document.
Filing Stats: 829 words · 3 min read · ~3 pages · Grade level 11.9 · Accepted 2024-10-30 16:30:27
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value CARM The Nasdaq Stock Mar
- $40,000 — receive (i) annual cash compensation of $40,000 for her service as a director and an ad
Filing Documents
- tm2426977d2_8k.htm (8-K) — 26KB
- 0001104659-24-112629.txt ( ) — 196KB
- carm-20241024.xsd (EX-101.SCH) — 3KB
- carm-20241024_lab.xml (EX-101.LAB) — 33KB
- carm-20241024_pre.xml (EX-101.PRE) — 22KB
- tm2426977d2_8k_htm.xml (XML) — 4KB
02 Departure of Directors or Certain Officers; Election of
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Director Resignation On October 24, 2024, Michael Torok notified Carisma Therapeutics Inc. (the "Company") of his decision to resign from the Company's board of directors (the "Board"), effective October 31, 2024. At the time of his resignation, Mr. Torok was a member of the audit committee. Mr. Torok's resignation from the Board was due to his other professional commitments and not a result of any disagreement with the Company's operations, policies or practices. Director Appointment On October 30, 2024, the Board elected Sohanya Cheng as a director of the Company, effective October 31, 2024. Ms. Cheng was appointed as a Class I director and will serve in accordance with the Company's amended and restated by-laws until the Company's 2027 annual meeting of stockholders and thereafter until her successor is duly elected and qualified or until her earlier death, resignation or removal. Ms. Cheng will serve on the audit committee, which will be comprised of Marella Thorell (Chair), Sanford Zweifach and Ms. Cheng, effective October 31, 2024. In accordance with the Company's non-employee director compensation policy, Ms. Cheng will receive (i) annual cash compensation of $40,000 for her service as a director and an additional cash retainer for any committees on which she serves and (ii) reimbursement for reasonable out-of-pocket business expenses incurred in connection with attending meetings of the Board and committees thereof. In addition, in accordance with the Company's non-employee director compensation policy, Ms. Cheng was granted a stock option under the Carisma Therapeutics Inc. 2014 Amended and Restated Stock Incentive Plan to purchase 38,700 shares of the Company's common stock at a per share exercise price equal to the closing price of the Company's common stock on October 31, 2024, the date of gr
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CARISMA THERAPEUTICS INC. By: /s/ Steven Kelly Date: October 30, 2024 Steven Kelly President and Chief Executive Officer